Trials / Withdrawn
WithdrawnNCT02277392
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase-I, dose escalation study to assess the safety and biological activity of cyclophosphamide/fludarabine lymphodepletion followed by adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood autologous T-cells, and recombinant human interleukin-18 (SB-485232, IL-18) treatment in adult patients with recurrent, Stage III or IV ovarian cancer, fallopian tube or primary peritoneal cancer who previously underwent induction vaccination with whole tumor vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells | |
| BIOLOGICAL | SB---485232 (Human recombinant Interleukin---18) |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-06-01
- First posted
- 2014-10-29
- Last updated
- 2018-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02277392. Inclusion in this directory is not an endorsement.